Bihua Chen
CIK 1599214 · Chairperson and CEO · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$476.99M
Companies
22
Total Filings
45
Lifetime Open-Market Net
$446.78M
Filer Profile
Reported Address
C/O CORMORANT ASSET MANAGEMENT, LP200 CLARENDON STREET, 50TH FLOOR
BOSTON, MA 02116
Related Filers
Cormorant Asset Management, LP — 118 joint filings, latest 2026-08-10
Cormorant Global Healthcare Master Fund, LP — 108 joint filings, latest 2026-08-10
Cormorant Private Healthcare Fund III LP — 51 joint filings, latest 2026-08-10
Cormorant Private Healthcare Fund II, LP — 29 joint filings, latest 2025-10-01
Cormorant Global Healthcare GP, LLC — 15 joint filings, latest 2018-11-02
Cormorant Private Healthcare Fund IV LP — 10 joint filings, latest 2025-10-01
Cormorant Private Healthcare Fund V LP — 7 joint filings, latest 2026-08-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBOT | Director | 1,905,046 | $4.95 | $9.43M | $0 | 3 | 2026-07-06 |
| HLXC | Chairperson and CEO | 497,500 | $10.80 | $5.37M | $16.00M | 2 | 2026-01-28 |
| EYPT | 10%+ Owner | 8,265,000 | $4.23 | $34.96M | $234.19M | 5 | 2025-12-08 |
| MLTX | 10%+ Owner | 1,994,173 | $12.51 | $24.95M | -$154.25M | 6 | 2025-10-01 |
| OKUR | 0 | $3.10 | $0 | -$20.18M | 1 | 2025-05-19 | |
| AARD | 800,189 | $5.13 | $4.10M | $6.00M | 1 | 2025-02-19 | |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | CEO and Chairperson | — | $9.90 | — | $0 | 1 | 2025-02-10 |
| DRUG | 10%+ Owner | 1,059,331 | $63.18 | $66.93M | $17.70M | 2 | 2024-11-06 |
| IMRX | 10%+ Owner | 3,294,173 | $4.27 | $14.07M | -$15.64M | 2 | 2024-04-03 |
| CRBP | 10%+ Owner | 1,475,000 | $8.12 | $11.98M | $70.09M | 2 | 2024-02-06 |
| Ambrx Biopharma Inc. (AMAM) Delisted | 10%+ Owner | 68,714,590 | $28.00 | $1.92B | $78.50M | 1 | 2023-09-19 |
| BMEA | Director | 3,570,872 | $1.74 | $6.21M | $0 | 1 | 2023-06-16 |
| ERAS | Director | 10,813,246 | $15.88 | $171.71M | $8.67M | 3 | 2022-12-21 |
| PYXS | Director | 668,854 | $3.21 | $2.15M | $28.80M | 1 | 2021-10-15 |
| BCAB | Director | 45,841 | $1.74 | $79.5K | $57.60M | 1 | 2020-12-22 |
| OLMA | Director | 3,270,544 | $10.22 | $33.42M | $40.38M | 1 | 2020-11-23 |
| MoonLake Immunotherapeutics (HLXA) Delisted | CEO and Chairman | 430,000 | $13.25 | $5.70M | $4.30M | 1 | 2020-10-22 |
| RNA | Director | 2,214,545 | $10.36 | $22.94M | $21.60M | 1 | 2020-06-18 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 3,122,367 | $76.01 | $237.33M | $14.40M | 3 | 2019-08-12 |
| Axonics, Inc. (AXNX) Delisted | Director | 599,999 | $70.98 | $42.59M | $8.00M | 1 | 2018-11-02 |
| KNSA | Director | 900,443 | $76.27 | $68.68M | $5.00M | 1 | 2018-05-31 |
| KINETA, INC./DE (PTI) Delisted | Director | 189,136 | — | — | $25.62M | 4 | 2016-12-14 |
Recent Filings · Page 5 of 5
45 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-31 | KNSA | Mixed | +3,601,772 | $5.00M | EDGAR |
| 2016-12-14 | KINETA, INC./DE (PTI) Delisted | Buy (P) | +485,204 | $5.25M | EDGAR |
| 2016-12-09 | KINETA, INC./DE (PTI) Delisted | Buy (P) | +177,668 | $1.92M | EDGAR |
| 2016-12-01 | KINETA, INC./DE (PTI) Delisted | Buy (P) | +681,564 | $6.98M | EDGAR |
| 2016-11-14 | KINETA, INC./DE (PTI) Delisted | Buy (P) | +1,038,000 | $11.47M | EDGAR |
Showing 41–45 of 45
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.